Bristol Myers: positive data in lung cancer

(CercleFinance.com) - Six-Year Outcomes from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer.


Data from longest reported follow-up for a Phase 3 trial with immunotherapy in metastatic non-small cell lung cancer demonstrate consistent, durable benefits of Opdivo plus Yervoy vs. chemotherapy at six years, regardless of PD-L1 expression

Opdivo plus Yervoy combination more than tripled overall survival rate at six years compared to chemotherapy in patients with PD-L1 expression <1% in an exploratory analysis

Updated data to be presented and featured in the official press program at IASLC 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer.

Copyright (c) 2023 CercleFinance.com. All rights reserved.